MA46255A - Vaccins anticancéreux - Google Patents
Vaccins anticancéreuxInfo
- Publication number
- MA46255A MA46255A MA046255A MA46255A MA46255A MA 46255 A MA46255 A MA 46255A MA 046255 A MA046255 A MA 046255A MA 46255 A MA46255 A MA 46255A MA 46255 A MA46255 A MA 46255A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer vaccines
- vaccines
- cancer
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245129P | 2015-10-22 | 2015-10-22 | |
| US201562245031P | 2015-10-22 | 2015-10-22 | |
| US201562247472P | 2015-10-28 | 2015-10-28 | |
| US201562247317P | 2015-10-28 | 2015-10-28 | |
| US201662368810P | 2016-07-29 | 2016-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46255A true MA46255A (fr) | 2019-07-31 |
Family
ID=58558197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046255A MA46255A (fr) | 2015-10-22 | 2016-10-21 | Vaccins anticancéreux |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3364949A4 (fr) |
| JP (3) | JP2018532777A (fr) |
| CN (2) | CN114404581A (fr) |
| AU (3) | AU2016341309A1 (fr) |
| CA (1) | CA3003090A1 (fr) |
| MA (1) | MA46255A (fr) |
| WO (1) | WO2017070618A1 (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2021109685A (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (fr) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Vaccins contre les maladies infectieuses |
| EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
| CA3002819A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre les maladies sexuellement transmissibles |
| MA47016A (fr) | 2015-10-22 | 2018-08-29 | Modernatx Inc | Vaccins contre les virus respiratoires |
| JP6925688B2 (ja) | 2015-10-22 | 2021-08-25 | モデルナティーエックス， インコーポレイテッド | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン |
| ES2924407T3 (es) | 2015-12-10 | 2022-10-06 | Modernatx Inc | Composiciones y procedimientos para el suministro de agentes terapéuticos |
| KR102533456B1 (ko) | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| CA3036831A1 (fr) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | Compositions d'arn de haute purete et procedes pour leur preparation |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| AU2017397458B2 (en) * | 2017-02-01 | 2025-07-10 | Modernatx, Inc. | RNA cancer vaccines |
| WO2018144775A1 (fr) * | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Compositions thérapeutiques immunomodulatrices d'arnm codant pour des peptides de mutation d'activation d'oncogènes |
| WO2018151816A1 (fr) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | Compositions immunogènes très puissantes |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| CA3083102A1 (fr) * | 2017-11-21 | 2019-05-31 | Modernatx, Inc. | Vaccins contre le virus d'epstein-barr |
| CN118512596A (zh) * | 2017-12-27 | 2024-08-20 | 武田药品工业株式会社 | 含核酸脂质纳米粒子及其用途 |
| WO2019148101A1 (fr) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Vaccins à base d'arn contre le vrs |
| MX2020008394A (es) * | 2018-02-12 | 2020-09-21 | Biontech Rna Pharmaceuticals Gmbh | Tratamiento que usa arn que codifica citoquinas. |
| EP3813848A4 (fr) * | 2018-06-27 | 2022-07-20 | ModernaTX, Inc. | Sélection personnalisée d'épitopes de vaccins contre le cancer |
| WO2020020444A1 (fr) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Vaccins individualisés pour le cancer |
| WO2020061284A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg et leurs utilisations |
| EP4509118A3 (fr) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | Lipides peg de haute pureté et leurs utilisations |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US20210381060A1 (en) * | 2018-10-29 | 2021-12-09 | Health Research, Inc. | Cancer specific immunotherapeutic targets generated by chemotherapeutic drug treatment |
| WO2020097291A1 (fr) * | 2018-11-07 | 2020-05-14 | Modernatx, Inc. | Vaccins à arn contre le cancer |
| WO2020099614A1 (fr) * | 2018-11-15 | 2020-05-22 | Nouscom Ag | Sélection de mutations de cancer pour la génération d'un vaccin personnalisé contre le cancer |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| WO2021016330A2 (fr) * | 2019-07-22 | 2021-01-28 | Oneskin, Inc. | Polypeptides ayant des effets anti-sénescence et leurs utilisations |
| WO2021076805A1 (fr) * | 2019-10-15 | 2021-04-22 | Moderna TX, Inc. | Arnm codant des polypeptides de modulation immunitaire et leurs utilisations |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| US20230022045A1 (en) * | 2019-12-03 | 2023-01-26 | Board Of Regents, The University Of Texas System | Combination therapies for the treatment of cancer |
| CN115768892A (zh) | 2020-03-09 | 2023-03-07 | 戴纳瓦克斯技术公司 | 包含tlr9激动剂的带状疱疹疫苗 |
| US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
| CN111773381A (zh) * | 2020-07-06 | 2020-10-16 | 贵阳市第二人民医院 | 一种靶向tem-1基因疫苗及其构建与应用 |
| WO2022009052A2 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
| WO2022120560A1 (fr) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | Immunosuppresseur sous forme posologique d'arnm et son application dans la préparation d'un médicament pour le traitement de tumeurs |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| TW202320842A (zh) * | 2021-07-29 | 2023-06-01 | 德商拜恩技術股份公司 | 用於治療黑色素瘤之組合物及方法 |
| EP4395748A1 (fr) | 2021-09-03 | 2024-07-10 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
| EP4419082A1 (fr) * | 2021-10-20 | 2024-08-28 | ModernaTX, Inc. | Solutions de substitution de produit médicamenteux |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4469091A1 (fr) | 2022-01-28 | 2024-12-04 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN119173270A (zh) * | 2022-06-30 | 2024-12-20 | Eps创药株式会社 | 舌下给药用疫苗组合物 |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| CN116083463B (zh) * | 2022-12-16 | 2024-06-21 | 四川大学华西医院 | 一种用于增强免疫疗法效果的mRNA及其在制备mRNA疫苗中的用途 |
| CN115671045B (zh) * | 2022-12-30 | 2023-04-07 | 华南理工大学 | 非肝靶向的核酸纳米制剂及其制备方法和应用 |
| CN120813369A (zh) * | 2023-01-17 | 2025-10-17 | 香港大学 | 通过递送mRNA的癌症免疫疗法 |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
| WO2025002352A1 (fr) | 2023-06-28 | 2025-01-02 | 上海瑞宏迪医药有限公司 | Composition pharmaceutique contenant un lipide cationique et son utilisation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| CN1129667C (zh) * | 2001-12-26 | 2003-12-03 | 中国人民解放军第二军医大学 | 治疗肿瘤的自体免疫细胞及其制备方法 |
| EP2569633B1 (fr) * | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur |
| HRP20250981T1 (hr) * | 2011-05-24 | 2025-10-24 | BioNTech SE | Individualizirana cjepiva protiv raka |
| EP3456316A1 (fr) * | 2011-07-06 | 2019-03-20 | GlaxoSmithKline Biologicals S.A. | Emulsions huile dans eau cationiques |
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| KR20140102759A (ko) * | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| WO2013143555A1 (fr) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| HK1206612A1 (en) * | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| EP2834259A4 (fr) * | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | Polynucléotides modifiés |
| EP2925348B1 (fr) * | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Vaccins individualisés pour le cancer |
| ES3032013T3 (en) * | 2013-03-15 | 2025-07-14 | Translate Bio Inc | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| AU2014315287A1 (en) * | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015061467A1 (fr) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Formulations de lipide pour l'administration d'arn messager |
| EP3556353A3 (fr) * | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Adjuvants de vaccins à nanoparticules lipidiques et systèmes d'administration d'antigènes |
| EP3328394A4 (fr) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | Arn épitope peptidiques concatémériques |
| EP3350157B1 (fr) * | 2015-09-17 | 2022-01-05 | Modernatx, Inc. | Composés et compositions pour l'administration intracellulaire d'agents thérapeutiques |
-
2016
- 2016-10-21 CA CA3003090A patent/CA3003090A1/fr active Pending
- 2016-10-21 EP EP16858398.7A patent/EP3364949A4/fr active Pending
- 2016-10-21 AU AU2016341309A patent/AU2016341309A1/en not_active Abandoned
- 2016-10-21 JP JP2018541087A patent/JP2018532777A/ja active Pending
- 2016-10-21 CN CN202111635839.9A patent/CN114404581A/zh active Pending
- 2016-10-21 WO PCT/US2016/058317 patent/WO2017070618A1/fr not_active Ceased
- 2016-10-21 MA MA046255A patent/MA46255A/fr unknown
- 2016-10-21 CN CN201680075024.0A patent/CN108430456B/zh active Active
-
2022
- 2022-12-22 JP JP2022205615A patent/JP7625568B2/ja active Active
-
2024
- 2024-01-23 AU AU2024200425A patent/AU2024200425B2/en active Active
-
2025
- 2025-01-22 JP JP2025009237A patent/JP2025063273A/ja active Pending
- 2025-05-07 AU AU2025203258A patent/AU2025203258A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180318409A1 (en) | 2018-11-08 |
| CN108430456B (zh) | 2022-01-18 |
| WO2017070618A1 (fr) | 2017-04-27 |
| JP2018532777A (ja) | 2018-11-08 |
| AU2016341309A1 (en) | 2018-06-07 |
| AU2024200425A1 (en) | 2024-02-15 |
| CN108430456A (zh) | 2018-08-21 |
| AU2025203258A1 (en) | 2025-05-29 |
| CA3003090A1 (fr) | 2017-04-27 |
| EP3364949A1 (fr) | 2018-08-29 |
| CN114404581A (zh) | 2022-04-29 |
| JP7625568B2 (ja) | 2025-02-03 |
| JP2023024669A (ja) | 2023-02-16 |
| AU2024200425B2 (en) | 2025-02-27 |
| JP2025063273A (ja) | 2025-04-15 |
| EP3364949A4 (fr) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46255A (fr) | Vaccins anticancéreux | |
| DK3393510T5 (da) | Zikavirusvaccine | |
| MA46378A (fr) | Vaccins hpv16 thérapeutiques | |
| GB201518684D0 (en) | Vaccine | |
| GB201410971D0 (en) | Vaccine | |
| PL3423087T3 (pl) | Skojarzona terapia przeciwnowotworowa | |
| MA41107A (fr) | Compositions anti-cancéreuses | |
| LT3226842T (lt) | Priešvėžinės kompozicijos | |
| LT3226843T (lt) | Priešvėžinės kompozicijos | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| DK3171700T3 (da) | Infusionsanlæg | |
| EP3273989C0 (fr) | Vaccin streptococcique | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| EP3560512A4 (fr) | Composition de vaccin contre le zona | |
| EP3344286A4 (fr) | Vaccins contre le cancer de l'ovaire | |
| GB201522132D0 (en) | Vaccine | |
| HUE054584T2 (hu) | Maropitant készítmény | |
| EP3334447A4 (fr) | Conjugués médicament-cck2r | |
| DK3205661T3 (da) | Hsp70-afledt immunitetsinducerende peptid | |
| EP3528843A4 (fr) | Vaccins anti-opioïdes | |
| DK3405212T3 (da) | Cancervacciner | |
| HUE064499T2 (hu) | Hiszton rákellenes vakcinák | |
| DK3155004T3 (da) | Vaccine til immunkompromitterede værter | |
| EP3395344A4 (fr) | Médicament | |
| HUE047581T2 (hu) | Készítmény |